Dr. Jean-Paul Kress, Chief Executive Officer Sung Lee, Chief Financial Officer Dr. Malte Peters, Chief Research & Development Officer Dr. Roland Wandeler, Chief Commercial Officer Dr. Marc Cluzel, Chairman of Supervisory Board
Products
Immunotherapy
Revenue
€327.7 million (2020)[1]
Operating income
€27.4 million (2020)[1]
Net income
€97.9 million (2020)[1]
Total assets
€1,659.5 million (end 2020)[1]
Total equity
€621.3 million (end 2020)[1]
Number of employees
615 (end 2020)[1]
Website
www.morphosys.com
MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases.[1][2][3] While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.
MorphoSys AG is listed on the Frankfurt Stock Exchange and on the US Nasdaq stock exchange. Novartis agreed to acquire the company in February 2024.
^ abcdefg"Annual Report 2020". MorphoSys. Retrieved 29 April 2021.
^"MorphoSys' therapeutic pipeline". MorphoSys.
^"Form 20-F". U.S. Securities and Exchange Commission.
are invalid because of obviousness." The German biotechnology company MorphoSys generates human antibodies using its phage display-based 'HuCal' (Human...
for the global development and commercialization of tafasitamab with MorphoSys. On March 3, 2020, the agreement received antitrust clearance and thus...
human antibody which has been developed by the biotechnology company MorphoSys. It can also be referred to as HuCAL antibody, HuCAL standing for Human...
More Than $10 Billion". WSJ. Retrieved 2023-12-01. AG, MorphoSys (26 January 2016). "MorphoSys Announces Clinical Milestone for Start of Bayer's Phase...
and Health Products Portal. 4 September 2020. Retrieved 18 March 2024. "MorphoSys' licensee Janssen receives Japanese approval for Tremfya to treat moderate...
Guangming; Kurdahi, F.J.; Bagherzadeh, N.; Filho, E.M. Chaves (2000-06-01). "MorphoSys: an integrated reconfigurable system for data-parallel and computation-intensive...
Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2). "Ianalumab - MorphoSys/Novartis". AdisInsight. Springer Nature Switzerland AG. van den Hoogen...
biotech-companies, like ADVA Optical Networking, GPC Biotech, MediGene and MorphoSys. In addition, the Max Planck Institute of Biochemistry and the Max Planck...
or Refractory Diffuse Large B-cell Lymphoma (DLBCL)" (Press release). MorphoSys AG. 31 July 2020. Archived from the original on 2 August 2020. Retrieved...
Texas-Austin MorphoSys: an integrated reconfigurable system for data-parallel and computation-intensive applications Design and implementation of the MorphoSys reconfigurable...
in development e.g. Juno JCAR015, Kite KTE-C19 CAR, Novartis CTL019, Morphosys MOR208, Macrogenics MGD011, Affimed AFM11 CD20 a type III transmembrane...
Elixent, NGEN, Polyp, MereGen, PACT XPP, Silicon Hive, Montium, Pleiades, Morphosys, and PiCoGA. Such designs were feasible due to the constant progress of...
Patients With Solid Tumors" at ClinicalTrials.gov "Annual Report 2012: Research and Development". MorphoSys. 2012. Retrieved 2017-03-24. v t e v t e...
The deal closed in April 2009. The unit became part of Sagem Morpho, which was renamed MorphoTrak. On March 26, 2008, Motorola's board of directors approved...
Recognition System (JFRS), which is integrated with PENN DOT's DMV photos (from MorphoTrust) and the Commonwealth Photo Imaging System (CPIN). This is used by...
Cortex-M0 core at a maximum clock rate of 48 MHz. Cortex-M0 options include the SysTick Timer. Memory: Static RAM consists of 4 / 6 / 8 / 16 / 32 KB general...
Global Information